elranatamab
pfizer
['cart,(-cartitude)', 'elranatamab']
in bcma exposed/refractory mm, elranatamab sc shows a response rate ~60%, crs ~59% (grade 1/2), icans in 3.6% (grade 1/2), median follow-up ~4 months. #cartsm #asco22 #asco22_szu #mediq22asco #eha2022
Chief of Myeloma @MSKCancerCenter | Chair @ALLIANCE_org #mmsm Comm. |Physician ? Provider| @ASH_hematology @ASTCT @ASCO |married to @ZainabShd | #BMTsm #CARTsm